Company Filing History:
Years Active: 2015
Title: Grundram Jung: Innovator in Anti-FLT3 Antibodies
Introduction
Grundram Jung is a notable inventor based in Rottenburg-Wendelsheim, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of anti-FLT3 antibodies. His work focuses on enhancing the efficacy of these antibodies for therapeutic applications.
Latest Patents
Jung holds a patent for anti-FLT3 antibodies, which feature a modified Fc region with amino acid substitutions 239D and 332E. This modification is designed to enhance antibody-dependent cell cytotoxicity (ADCC). The patent also encompasses pharmaceutical compositions containing these antibodies, nucleic acids encoding them, and methods for their use. He has 1 patent to his name.
Career Highlights
Currently, Grundram Jung is associated with Synimmune GmbH, a company that specializes in innovative antibody therapies. His work at Synimmune has positioned him as a key player in the development of novel treatments for various diseases.
Collaborations
Jung collaborates with esteemed colleagues, including Ludger Grosse-Hovest and Hans-Joerg Buehring. These partnerships enhance the research and development efforts within the company.
Conclusion
Grundram Jung's contributions to the field of biotechnology, particularly through his patent on anti-FLT3 antibodies, highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new therapeutic options.